AEON Biopharma Announces CEO Transition
AEON Biopharma (NYSE: AEON) announced a leadership transition as President and CEO Marc Forth steps down effective April 4, 2025, to pursue another opportunity. Forth will remain on the Board of Directors to provide strategic guidance. Chairman Jost Fischer will serve as Interim CEO while the Board searches for a permanent replacement.
The company, focused on developing botulinum toxin complex for therapeutic indications, is progressing with its 351(k) biosimilar regulatory pathway for ABP-450. The company expects to have a Biosimilar BPD Type 2a meeting with FDA in the second half of 2025, with current cash reserves sufficient to support operations through this milestone.
AEON Biopharma (NYSE: AEON) ha annunciato un cambiamento nella leadership poiché il Presidente e CEO Marc Forth si dimetterà a partire dal 4 aprile 2025, per perseguire un'altra opportunità. Forth rimarrà nel Consiglio di Amministrazione per fornire orientamenti strategici. Il Presidente Jost Fischer assumerà il ruolo di CEO ad interim mentre il Consiglio cerca un sostituto permanente.
L'azienda, focalizzata sullo sviluppo di complessi di tossina botulinica per indicazioni terapeutiche, sta avanzando con il suo percorso regolatorio biosimilare 351(k) per ABP-450. L'azienda prevede di avere un incontro Biosimilar BPD Tipo 2a con la FDA nella seconda metà del 2025, con riserve di cassa attuali sufficienti a sostenere le operazioni fino a questo traguardo.
AEON Biopharma (NYSE: AEON) anunció una transición en el liderazgo ya que el Presidente y CEO Marc Forth renunciará a partir del 4 de abril de 2025, para buscar otra oportunidad. Forth permanecerá en la Junta Directiva para proporcionar orientación estratégica. El Presidente Jost Fischer actuará como CEO interino mientras la Junta busca un reemplazo permanente.
La empresa, centrada en el desarrollo de un complejo de toxina botulínica para indicaciones terapéuticas, está avanzando en su camino regulatorio biosimilar 351(k) para ABP-450. La empresa espera tener una reunión de Biosimilar BPD Tipo 2a con la FDA en la segunda mitad de 2025, con reservas de efectivo actuales suficientes para apoyar las operaciones hasta este hito.
AEON Biopharma (NYSE: AEON)은 2025년 4월 4일부로 Marc Forth 사장이 사임하고 다른 기회를 추구한다고 발표했습니다. Forth는 전략적 지침을 제공하기 위해 이사회에 남을 것입니다. 회장 Jost Fischer는 이사회가 영구적인 후임자를 찾는 동안 임시 CEO로 활동할 예정입니다.
이 회사는 치료적 적응증을 위한 보툴리눔 독소 복합체 개발에 집중하고 있으며, ABP-450에 대한 351(k) 바이오시밀러 규제 경로를 진행하고 있습니다. 이 회사는 2025년 하반기에 FDA와 바이오시밀러 BPD 유형 2a 회의를 가질 것으로 예상하며, 현재 현금 보유액은 이 이정표를 달성하는 데 충분합니다.
AEON Biopharma (NYSE: AEON) a annoncé une transition de leadership, car le Président et CEO Marc Forth démissionnera à compter du 4 avril 2025, pour poursuivre une autre opportunité. Forth restera au Conseil d'Administration pour fournir des conseils stratégiques. Le Président Jost Fischer agira en tant que CEO par intérim pendant que le Conseil recherche un remplaçant permanent.
L'entreprise, axée sur le développement de complexes de toxine botulique pour des indications thérapeutiques, progresse dans son parcours réglementaire biosimilaire 351(k) pour ABP-450. L'entreprise s'attend à avoir une réunion Biosimilar BPD Type 2a avec la FDA dans la seconde moitié de 2025, avec des réserves de liquidités actuelles suffisantes pour soutenir les opérations jusqu'à ce jalon.
AEON Biopharma (NYSE: AEON) gab eine Führungsänderung bekannt, da Präsident und CEO Marc Forth am 4. April 2025 zurücktritt, um eine andere Gelegenheit zu verfolgen. Forth wird im Vorstand bleiben, um strategische Anleitungen zu geben. Vorsitzender Jost Fischer wird als Interims-CEO fungieren, während der Vorstand nach einem dauerhaften Nachfolger sucht.
Das Unternehmen, das sich auf die Entwicklung von Botulinumtoxin-Komplexen für therapeutische Anwendungen konzentriert, schreitet mit seinem 351(k) Biosimilar-Regulierungsweg für ABP-450 voran. Das Unternehmen erwartet, in der zweiten Hälfte des Jahres 2025 ein Biosimilar BPD Typ 2a Treffen mit der FDA abzuhalten, wobei die aktuellen Barreserven ausreichend sind, um die Operationen bis zu diesem Meilenstein zu unterstützen.
- Company has sufficient cash reserves to fund operations through key FDA meeting in H2 2025
- Pursuing 351(k) biosimilar pathway could enable single FDA approval for multiple BOTOX indications
- Maintaining leadership continuity with departing CEO remaining on Board
- Unexpected CEO departure could create temporary leadership uncertainty
- Interim CEO arrangement may delay strategic decisions until permanent replacement is found
Insights
This CEO transition at AEON Biopharma introduces an element of uncertainty at a critical regulatory juncture. Marc Forth's departure comes as the company navigates a pivotal 351(k) biosimilar pathway for its ABP-450 product, which aims to compete with BOTOX across all therapeutic indications through a single FDA approval approach.
The appointment of Chairman Jost Fischer as interim CEO provides some stability, given his 8-year tenure on AEON's board and previous leadership experience as Sirona's CEO. The fact that Forth will remain on the board offers additional continuity during this transition period.
Critically, the company has confirmed sufficient cash runway through their anticipated FDA Biosimilar BPD Type 2a meeting in H2 2025. This timeline assurance is important for a clinical-stage company with no commercial products yet.
While leadership changes always create execution risk, several factors mitigate concerns: 1) The board is already evaluating "several qualified candidates," suggesting a replacement could be named relatively soon; 2) Fischer's long-standing relationship with the company indicates institutional knowledge preservation; and 3) The explicit statement that programs will "continue to move forward without delay" provides some reassurance regarding operational continuity.
For a
– Marc Forth Steps Down as President and CEO to Pursue Another Opportunity; will remain on the Board of Directors –
– Jost Fischer, Chairman of AEON, will assume the role of interim CEO –
IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced today a leadership transition under which Marc Forth is stepping down as President and Chief Executive Officer of the Company to pursue another opportunity, effective April 4, 2025. Mr. Forth will continue with the Company as a member of its board of directors (the “Board”), through which he will continue to advise the Company’s management team and provide strategic guidance. The Board has appointed Jost Fischer, the current Chairman of the Board, to serve as Interim Chief Executive Officer following Mr. Forth’s departure while the Board identifies a replacement chief executive officer. The Board is actively considering several qualified candidates.
“On behalf of the Board, I want to thank Marc for his invaluable contributions to AEON over the last several years and his dedication to exhaustively evaluating all opportunities for the Company to execute its growth strategy. As a result of these efforts, the Company is making steady progress along a 351(k) biosimilar regulatory pathway that could allow it to bring ABP-450 to the U.S. market for all of BOTOX’s currently approved and future therapeutic indications under a single FDA approval,” commented Mr. Fischer. “I look forward to working with the AEON team and the Board to ensure our program for ABP-450 continues to move forward without delay. We believe our current cash balance will allow us to work through our Biosimilar BPD Type 2a meeting with FDA anticipated in the second half of 2025. We look forward to announcing the results of that meeting and next steps in our development program.”
Jost Fischer has served as a member of the Company’s Board since February 2017. Mr. Fischer is the co-owner of Dental Innovations BVBA. Mr. Fischer served as a member and the chairman of the board of directors and as Chief Executive Officer of Sirona from June 2006 to February 2013, as Chief Executive Officer from April 2002 to February 2013, and as President from April 2002 to September 2010. Prior to joining Sirona, Mr. Fischer served as President and Chief Executive Officer of The Hoermann Group, an international conglomerate in the telecommunication and automotive industry, and held senior management positions with PWA Group, a European paper group, including President and Chief Executive Officer of PWA’s printing division and President and Chief Executive Officer of PWA Dekor GmbH. In addition, Mr. Fischer serves on the board of directors of several private companies. He received a Master’s degree in Economics from the University of Saarbruecken, Germany.
About AEON Biopharma
AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurosciences market. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau. ABP-450 is manufactured by Daewoong in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada and European Medicines Agency. The product is approved as a biosimilar in Mexico and India. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. The Company has built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization. To learn more about AEON, visit www.aeonbiopharma.com.
Forward-Looking Statements
Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or AEON’s future financial or operating performance. For example, statements regarding meetings with the FDA, the timing of primary comparative analytical studies, and potential determination that ABP-450 is highly similar to the reference product for currently approved and future therapeutic indications are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "plan", "possible", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential", "continue" or "could", or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements.
These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by AEON and its management, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) the outcome of any legal proceedings that may be instituted against AEON or others; (ii) AEON’s future capital requirements; (iii) AEON’s ability to raise financing in the future; (iv) AEON’s ability to maintain the cash balance required to work through our Biosimilar BPD Type 2a meeting with the FDA; (v) AEON’s ability to continue to meet continued stock exchange listing standards; (vi) the possibility that AEON may be adversely affected by other economic, business, regulatory, and/or competitive factors; (vii) AEON’s ability to progress along a 351(k) biosimiliar pathway to allow ABP-450 to be approved as a biosimilar to BOTOX under a single FDA approval; (viii) the outcomes from any meetings or discussions with regulatory authorities; and (ix) other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s filings with the Securities and Exchange Commission (the "SEC"), which are available on the SEC’s website at www.sec.gov.
Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. AEON does not undertake any duty to update these forward-looking statements.
Contacts
Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
Source: AEON Biopharma
